Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1932 1
1953 1
1954 3
1957 1
1958 5
1959 1
1961 1
1962 1
1963 1
1964 1
1965 2
1966 2
1967 2
1968 1
1969 4
1970 2
1971 1
1972 2
1973 1
1976 1
1977 2
1978 2
1979 1
1980 2
1981 2
1982 1
1983 3
1985 4
1986 4
1987 1
1988 4
1989 2
1991 6
1992 2
1993 5
1994 5
1995 7
1996 9
1997 8
1998 17
1999 14
2000 18
2001 14
2002 29
2003 21
2004 42
2005 47
2006 46
2007 24
2008 31
2009 21
2010 20
2011 30
2012 32
2013 28
2014 27
2015 27
2016 18
2017 21
2018 26
2019 29
2020 17
2021 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 16452343

651 results
Results by year
Filters applied: . Clear all
Page 1
A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ; Protocol 014 Study Group for ProQuad. Reisinger KS, et al. Pediatrics. 2006 Feb;117(2):265-72. doi: 10.1542/peds.2005-0092. Pediatrics. 2006. PMID: 16452343 Clinical Trial.
Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
Bernstein HH, Eves K, Campbell K, Black SB, Twiggs JD, Reisinger KS, Conti RM, Flodmark CE, Rombo L, Klopfer S, Schödel F, Hartzel J, Kuter BJ; Refrigerator-Stable Formulation Study Group for ProQuad. Bernstein HH, et al. Pediatrics. 2007 Jun;119(6):e1299-305. doi: 10.1542/peds.2006-2283. Epub 2007 May 14. Pediatrics. 2007. PMID: 17502347 Clinical Trial.
Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T, Baer M, Willems P. Vesikari T, et al. Pediatr Infect Dis J. 2007 Feb;26(2):153-8. doi: 10.1097/01.inf.0000250689.09396.21. Pediatr Infect Dis J. 2007. PMID: 17259879 Clinical Trial.
Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Marin M, et al. MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12. MMWR Recomm Rep. 2010. PMID: 20448530 Free article.
Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha M, Willems P. Halperin SA, et al. Vaccine. 2009 May 5;27(20):2701-6. doi: 10.1016/j.vaccine.2009.02.044. Epub 2009 Feb 24. Vaccine. 2009. PMID: 19428882 Clinical Trial.
The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ; Consistency Lot Study Group for ProQuad. Lieberman JM, et al. Pediatr Infect Dis J. 2006 Jul;25(7):615-22. doi: 10.1097/01.inf.0000220209.35074.0b. Pediatr Infect Dis J. 2006. PMID: 16804432 Clinical Trial.
Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P. Schuster V, et al. Pediatr Infect Dis J. 2008 Aug;27(8):724-30. doi: 10.1097/INF.0b013e318170bb22. Pediatr Infect Dis J. 2008. PMID: 18600190 Clinical Trial.
Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM; LAIV Study Group. Nolan T, et al. Pediatrics. 2008 Mar;121(3):508-16. doi: 10.1542/peds.2007-1064. Pediatrics. 2008. PMID: 18310199 Clinical Trial.
Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P, Lim FS, Han HH, Willems P. Goh P, et al. Infection. 2007 Oct;35(5):326-33. doi: 10.1007/s15010-007-6337-z. Epub 2007 Aug 20. Infection. 2007. PMID: 17710370 Clinical Trial.
Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, Brown ML, Eves KA, Klopfer SO, Schödel F, Kuter BJ. Shinefield H, et al. Pediatr Infect Dis J. 2005 Aug;24(8):665-9. doi: 10.1097/01.inf.0000172902.25009.a1. Pediatr Infect Dis J. 2005. PMID: 16094217 Clinical Trial.
651 results
Jump to page
Feedback